Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May 20;15(5):e39261.
doi: 10.7759/cureus.39261. eCollection 2023 May.

Berberine for Adjunct/Alternative Treatment of Dyslipidemia: A Literature Review

Endurance O Evbayekha  1 , Elochukwu U Nwachukwu  2 , Elham Nikravesh  3 , Valene Rosas  4 , Chinwendu A Onuegbu  5 , Obinna F Egwuonwu  6 , Osazee Eguagie  7 , Ogochukwu E Chioma  8 , Awanwosa V Agho  9 , Kemar A Samuels  10 , Anthony Willie  11 , Jane N Nwafor  12 , Laura N Esene-Akhideno  13 , Aisha O Adigun  14
Affiliations
Review

Berberine for Adjunct/Alternative Treatment of Dyslipidemia: A Literature Review

Endurance O Evbayekha et al. Cureus. .

Abstract

Berberine (BBR) is an ancient plant popular in China and is used to treat dyslipidemia, among other cardiovascular and metabolic-related diseases. BBR has historically been regarded as having multiple benefits, with a few clinical trials indicating this fact. We searched PubMed, Embase, and Google Scholar with the following keywords: Berberidaceae, berberine, Berberis spp., dyslipidemia, atherosclerosis, and inflammation. We synthesized the information within the literature to provide an updated review of BBR, its potential, and its applicability in real-world medicine in the future. This review sought to evaluate the literature and advancement in BBR's efficacy regarding dyslipidemia, inflammation, and atherosclerosis.

Keywords: atherosclerosis; berberidaceae; berberine; berberis spp; dyslipidemia; inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Illustration of the literature search process
See this image and copyright information in PMC

References

    1. World Health Organization. Cardiovascular diseases (CVDs) [ Jan; 2023 ]. 2021. https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-dise... https://www.who.int/en/news-room/fact-sheets/detail/cardiovascular-dise...
    1. Current knowledge and pharmacological profile of berberine: an update. Kumar A, Ekavali Ekavali, Chopra K, Mukherjee M, Pottabathini R, Dhull DK. https://pubmed.ncbi.nlm.nih.gov/26092760/ Eur J Pharmacol. 2015;761:288–297. - PubMed
    1. The inflammatory processes in atherogenesis. (Article in Polish) Cichoń N, Lach D, Dziedzic A, Bijak M, Saluk J. https://pubmed.ncbi.nlm.nih.gov/28333905/ Pol Merkur Lekarski. 2017;42:125–128. - PubMed
    1. How to balance cardiorenometabolic benefits and risks of statins. Lim S, Oh PC, Sakuma I, Koh KK. https://pubmed.ncbi.nlm.nih.gov/24973595/ Atherosclerosis. 2014;235:644–648. - PubMed
    1. Atherosclerosis: current pathogenesis and therapeutic options. Weber C, Noels H. Nat Med. 2011;17:1410–1422. - PubMed

LinkOut - more resources